COMMUNIQUÉS West-GlobeNewswire

-
PharmaTher Provides Update of its Priority Original Abbreviated New Drug Application for Ketamine
16/04/2024 -
MIMEDX to Host First Quarter 2024 Operating and Financial Results Conference Call on April 30
16/04/2024 -
REPEAT – MEDIA ADVISORY: Press conferences with patients who have been charged user fees of hundreds or even thousands of dollars at for-profit surgery clinics
16/04/2024 -
Acumen Pharmaceuticals Presents First Comprehensive Clinical and Biomarker Data for Sabirnetug (ACU193) at American Academy of Neurology 2024 Annual Meeting
16/04/2024 -
Recursion Appoints Najat Khan, PhD, as Chief R&D Officer and Chief Commercial Officer
16/04/2024 -
New Studies Prove the Clinical Benefits of Daxor’s Blood Volume (BVA-100TM) Diagnostic In Ambulatory Heart Failure Patients For Measurement of Congestion
16/04/2024 -
Provectus Biopharmaceuticals Announces Management Additions and Reiterates Commitment to Shareholder Value Creation
16/04/2024 -
GeneType Clinicians’ Adoption Growing - Sales up 5-Fold Year on Year
16/04/2024 -
Monopar Announces Filing of Patent Protecting MNPR-101 Radiopharma Optimization Findings
16/04/2024 -
Vittoria Biotherapeutics Announces Keith Westby as Chief Operating Officer
16/04/2024 -
Compass Therapeutics Announces First Patient Dosed in the Phase 1 Study of CTX-8371 in Patients with Solid Tumors
16/04/2024 -
Certara Launches Cloud Platform to Further Unify its End-to-End Scientific Software Platform
16/04/2024 -
FountainRx Selects Inovalon’s ScriptMed® Software To Enhance Patient Care and Scale Specialty and Infusion Pharmacy Services
16/04/2024 -
Enlivex Announces Authorization from the Danish Regulatory Agency for the Company’s Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Patients with Knee Osteoarthritis
16/04/2024 -
BioRestorative Therapies Announces FDA Clearance of Phase 2 BRTX-100 Clinical Study Protocol Amendment
16/04/2024 -
Lexeo Therapeutics Granted FDA Fast Track Designation for LX2006, an AAV-Based Gene Therapy Candidate for the Treatment of Friedreich’s Ataxia Cardiomyopathy
16/04/2024 -
Organogenesis Holdings Inc. to Report First Quarter of Fiscal Year 2024 Financial Results on May 9, 2024
16/04/2024 -
Southern California Clinic Signs Multi-Year Deal for MedMatrix AI Platform
16/04/2024 -
Eloxx Pharmaceuticals Provides ELX-02 and ZKN-013 Program Updates
16/04/2024
Pages